Ann J. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ann J. Lee has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Scott M. Hayes
Department of Psychology, The Ohio State University, Columbus, USA
6 shared publications - Jessica Stark
The Ohio State University, Columbus, OH, USA
2 shared publications Alex Buga
Department of Human Sciences, The Ohio State University, Columbus, USA
1 shared publicationAshwini Chebbi
Department of Human Sciences, The Ohio State University, Columbus, USA
1 shared publicationBradley T. Robinson
Department of Human Sciences, The Ohio State University, Columbus, USA
1 shared publicationChristopher D. Crabtree
Department of Human Sciences, The Ohio State University, Columbus, USA
1 shared publication
Latest Publications
- Open Access
- 10 September 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-11
A pilot study examining a ketogenic diet as an adjunct therapy in college students with major depressive disorder
A ketogenic diet (KD) has shown promise as an adjunctive therapy for neurological and neuropsychiatric disorders, including bipolar disorder and major depressive disorder (MDD). We examined tolerance for a KD in young adults with MDD and assessed symptoms of depression and metabolic health. Students (n = 24) with a confirmed diagnosis of MDD at baseline receiving standard of care counseling and/or medication treatment were enrolled in a 10–12 week KD intervention that included partial provision of ketogenic-appropriate food items, frequent dietary counseling, and daily morning tracking of capillary R-beta-hydroxybutyrate (R-BHB). Primary outcome measures for mood symptoms included the Patient Health Questionnaire (PHQ-9) and Hamilton Rating Scale for Depression (HRSD). Additional outcomes included body composition, neurocognitive function, and blood hormonal and inflammatory markers. Sixteen students (10 women, 6 men, mean age 24 yr) completed the intervention. Nutritional ketosis (R-BHB > 0.5 mM) was achieved 73% of the time. Depressive symptoms decreased by 69% (PHQ-9) and 71% (HRSD) post-intervention (p < 0.001), with improvement occurring within 2–6 weeks. Global well-being increased nearly 3-fold (p < 0.001). Participants lost body mass (−6.2%; p = 0.002) and fat mass (−13.0%; p < 0.001). Serum leptin decreased (−52%; p = 0.009) and brain-derived neurotropic factor increased (+32%; p = 0.029). Performance improved on several cognitive tasks. In students with mild to moderate depression based on PHQ-9 and HRSD, implementation of a WFKD for 10–12 weeks is a feasible adjunctive therapy and may be associated with improvements in depression symptoms, well-being, body composition, and cognition.
- 10 September 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-11
Open AccessA pilot study examining a ketogenic diet as an adjunct therapy in college students with major depressive disorder
A ketogenic diet (KD) has shown promise as an adjunctive therapy for neurological and neuropsychiatric disorders, including bipolar disorder and major depressive disorder (MDD). We examined tolerance for a KD in young adults with MDD and assessed symptoms of depression and metabolic health. Students (n = 24) with a confirmed diagnosis of MDD at baseline receiving standard of care counseling and/or medication treatment were enrolled in a 10–12 week KD intervention that included partial provision of ketogenic-appropriate food items, frequent dietary counseling, and daily morning tracking of capillary R-beta-hydroxybutyrate (R-BHB). Primary outcome measures for mood symptoms included the Patient Health Questionnaire (PHQ-9) and Hamilton Rating Scale for Depression (HRSD). Additional outcomes included body composition, neurocognitive function, and blood hormonal and inflammatory markers. Sixteen students (10 women, 6 men, mean age 24 yr) completed the intervention. Nutritional ketosis (R-BHB > 0.5 mM) was achieved 73% of the time. Depressive symptoms decreased by 69% (PHQ-9) and 71% (HRSD) post-intervention (p < 0.001), with improvement occurring within 2–6 weeks. Global well-being increased nearly 3-fold (p < 0.001). Participants lost body mass (−6.2%; p = 0.002) and fat mass (−13.0%; p < 0.001). Serum leptin decreased (−52%; p = 0.009) and brain-derived neurotropic factor increased (+32%; p = 0.029). Performance improved on several cognitive tasks. In students with mild to moderate depression based on PHQ-9 and HRSD, implementation of a WFKD for 10–12 weeks is a feasible adjunctive therapy and may be associated with improvements in depression symptoms, well-being, body composition, and cognition.
- Open Access
- 7 August 2025
- Published by Center for Open Science in PsyArXiv
Hippocampal Volume Moderates the Association between Cerebrospinal Fluid Growth-Associated Protein 43 and Episodic Memory Performance in Older Adults
This study examined the relationships between fluid and imaging biomarkers associated with memory (cerebrospinal fluid growth-associated protein 43 [CSF GAP-43] and hippocampal volume) and episodic memory performance in 586 older adults (mean age = 72.6 years, SD = 7.2) from the Alzheimer’s Disease Neuroimaging Initiative who completed CSF collection, Magnetic Resonance Imaging, and neuropsychological testing. Hierarchical linear regressions assessed whether FreeSurfer-derived total hippocampal volume or hippocampal subfield volume (subiculum, presubiculum, dentate gyrus, CA1) moderated the association between GAP-43 and episodic memory performance. GAP-43 and hippocampal volume were independently associated with episodic memory performance. Greater GAP-43 was associated with lower episodic memory performance in older adults with average or below-average (-1 SD) total and subfield (subiculum, presubiculum, dentate gyrus) hippocampal volume. No associations were observed in participants with above-average (+1 SD) volume. These findings suggest that GAP-43 may serve as a biomarker correlate of episodic memory impairment in those with average or below-average hippocampal volume.
- 7 August 2025
- Published by Center for Open Science in PsyArXiv
Open AccessHippocampal Volume Moderates the Association between Cerebrospinal Fluid Growth-Associated Protein 43 and Episodic Memory Performance in Older Adults
This study examined the relationships between fluid and imaging biomarkers associated with memory (cerebrospinal fluid growth-associated protein 43 [CSF GAP-43] and hippocampal volume) and episodic memory performance in 586 older adults (mean age = 72.6 years, SD = 7.2) from the Alzheimer’s Disease Neuroimaging Initiative who completed CSF collection, Magnetic Resonance Imaging, and neuropsychological testing. Hierarchical linear regressions assessed whether FreeSurfer-derived total hippocampal volume or hippocampal subfield volume (subiculum, presubiculum, dentate gyrus, CA1) moderated the association between GAP-43 and episodic memory performance. GAP-43 and hippocampal volume were independently associated with episodic memory performance. Greater GAP-43 was associated with lower episodic memory performance in older adults with average or below-average (-1 SD) total and subfield (subiculum, presubiculum, dentate gyrus) hippocampal volume. No associations were observed in participants with above-average (+1 SD) volume. These findings suggest that GAP-43 may serve as a biomarker correlate of episodic memory impairment in those with average or below-average hippocampal volume.
- Open Access
- 20 July 2025
- Published by Center for Open Science in PsyArXiv
Exploring the relative contributions of multiple modifiable physical attributes to executive function and episodic memory performance in older adults
Background: The majority of studies examining the relationship between fitness and cognition examine a single physical attribute. Here, we assessed the relative contributions of multiple modifiable physical attributes and demographic variables to cognition in healthy older adults.Methods: Older adults (N = 619; mean age = 74.9, SD = 6.9) completed multiple physical attribute assessments (walking speed, respiratory function, grip strength, BMI) and cognitive tasks as part of the Health and Retirement Study. Principal components analysis was used to create cognitive composite scores, which revealed two domains: executive functions/processing speed and episodic memory. Lindeman, Merenda, and Gold analysis was employed to assess the relative importance of demographic and modifiable physical attributes to each cognitive domain.Results: Age, education, walking speed, and respiratory function explained the greatest amount of variance in the relative importance analysis for both executive functions/processing speed and episodic memory. Modifiable variables, including walking speed and respiratory function, accounted for similar amounts of variance as age and education in predicting executive functions/processing speed performance. After controlling for demographic variables, modifiable physical performance variables of walking speed and respiratory function collectively accounted for an additional 9.9% and 3.3% variance in executive functions/processing speed and episodic memory, respectively.Conclusions: These results indicated that modifiable physical performance variables are differentially associated with cognitive performance. Fitness indicators can account for similar amounts of variance as age in executive functions/processing speed in healthy older adults.
- 20 July 2025
- Published by Center for Open Science in PsyArXiv
Open AccessExploring the relative contributions of multiple modifiable physical attributes to executive function and episodic memory performance in older adults
Background: The majority of studies examining the relationship between fitness and cognition examine a single physical attribute. Here, we assessed the relative contributions of multiple modifiable physical attributes and demographic variables to cognition in healthy older adults.Methods: Older adults (N = 619; mean age = 74.9, SD = 6.9) completed multiple physical attribute assessments (walking speed, respiratory function, grip strength, BMI) and cognitive tasks as part of the Health and Retirement Study. Principal components analysis was used to create cognitive composite scores, which revealed two domains: executive functions/processing speed and episodic memory. Lindeman, Merenda, and Gold analysis was employed to assess the relative importance of demographic and modifiable physical attributes to each cognitive domain.Results: Age, education, walking speed, and respiratory function explained the greatest amount of variance in the relative importance analysis for both executive functions/processing speed and episodic memory. Modifiable variables, including walking speed and respiratory function, accounted for similar amounts of variance as age and education in predicting executive functions/processing speed performance. After controlling for demographic variables, modifiable physical performance variables of walking speed and respiratory function collectively accounted for an additional 9.9% and 3.3% variance in executive functions/processing speed and episodic memory, respectively.Conclusions: These results indicated that modifiable physical performance variables are differentially associated with cognitive performance. Fitness indicators can account for similar amounts of variance as age in executive functions/processing speed in healthy older adults.
- Open Access
- 24 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcaf068
Neuronal and glial dysfunction, white matter hyperintensities and cognition in ageing and Alzheimer’s disease
This cross-sectional study examined associations between multiple fluid biomarkers of neuronal and glial dysfunction (plasma neurofilament light chain, CSF growth-associated protein 43 and CSF soluble triggering receptor expressed on myeloid cells 2), total white matter hyperintensity volume and episodic memory and executive function performance in the context of Alzheimer’s disease biomarker status. A total of 563 participants (mean age = 71.9 years, standard deviation = 7.2) from the Alzheimer’s Disease Neuroimaging Initiative were classified by the amyloid-β/tau/neurodegeneration framework into no Alzheimer’s disease pathology (n = 176), suspected non-Alzheimer’s disease pathophysiology (n = 87) or Alzheimer’s disease continuum (n = 300) groups. Participants completed baseline neuropsychological assessment, plasma/CSF biomarker collection and MRI. Analyses explored the relative contributions of biomarkers to episodic memory and executive function performance and whether relationships varied by amyloid-β/tau/neurodegeneration group status. Across all participants, neurofilament light chain (β^= −0.14, P < 0.001) and growth-associated protein 43 (β^= −0.13, P < 0.001) were the strongest biomarkers associated with episodic memory performance, such that greater levels were associated with worse episodic memory. There was a group by growth-associated protein 43 interaction with episodic memory: greater growth-associated protein 43 was associated with lower episodic memory performance in participants classified as Alzheimer’s disease continuum relative to the no Alzheimer’s disease pathology group (β^= −0.26, P < 0.001). No robust associations between biomarkers and executive function performance or between soluble triggering receptor expressed on myeloid cells 2, white matter hyperintensity volume and cognition were observed. Biomarkers of neuro-axonal injury and synaptic dysfunction may independently contribute to episodic memory performance across participants with differing amyloid-β/tau/neurodegeneration profiles. Growth-associated protein 43 may predict worse episodic memory performance in participants with greater Alzheimer’s disease pathology. These biomarkers of neuronal dysfunction may serve as domain-specific cognitive correlates in the context of Alzheimer’s disease biomarker status.
- 24 December 2024
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (1) , fcaf068
Open AccessNeuronal and glial dysfunction, white matter hyperintensities and cognition in ageing and Alzheimer’s disease
This cross-sectional study examined associations between multiple fluid biomarkers of neuronal and glial dysfunction (plasma neurofilament light chain, CSF growth-associated protein 43 and CSF soluble triggering receptor expressed on myeloid cells 2), total white matter hyperintensity volume and episodic memory and executive function performance in the context of Alzheimer’s disease biomarker status. A total of 563 participants (mean age = 71.9 years, standard deviation = 7.2) from the Alzheimer’s Disease Neuroimaging Initiative were classified by the amyloid-β/tau/neurodegeneration framework into no Alzheimer’s disease pathology (n = 176), suspected non-Alzheimer’s disease pathophysiology (n = 87) or Alzheimer’s disease continuum (n = 300) groups. Participants completed baseline neuropsychological assessment, plasma/CSF biomarker collection and MRI. Analyses explored the relative contributions of biomarkers to episodic memory and executive function performance and whether relationships varied by amyloid-β/tau/neurodegeneration group status. Across all participants, neurofilament light chain (β^= −0.14, P < 0.001) and growth-associated protein 43 (β^= −0.13, P < 0.001) were the strongest biomarkers associated with episodic memory performance, such that greater levels were associated with worse episodic memory. There was a group by growth-associated protein 43 interaction with episodic memory: greater growth-associated protein 43 was associated with lower episodic memory performance in participants classified as Alzheimer’s disease continuum relative to the no Alzheimer’s disease pathology group (β^= −0.26, P < 0.001). No robust associations between biomarkers and executive function performance or between soluble triggering receptor expressed on myeloid cells 2, white matter hyperintensity volume and cognition were observed. Biomarkers of neuro-axonal injury and synaptic dysfunction may independently contribute to episodic memory performance across participants with differing amyloid-β/tau/neurodegeneration profiles. Growth-associated protein 43 may predict worse episodic memory performance in participants with greater Alzheimer’s disease pathology. These biomarkers of neuronal dysfunction may serve as domain-specific cognitive correlates in the context of Alzheimer’s disease biomarker status.
- Open Access
- 18 September 2024
- Published by Center for Open Science in PsyArXiv
Neuronal and Glial Dysfunction, White Matter Hyperintensities, and Cognition in Aging and Alzheimer’s Disease
This cross-sectional study examined associations between multiple fluid biomarkers of neuronal and glial dysfunction (plasma neurofilament light chain, CSF growth-associated protein 43, CSF soluble triggering receptor expressed on myeloid cells 2 [sTREM2]), total white matter hyperintensity volume, and episodic memory and executive function performance in the context of Alzheimer’s disease biomarker status. 563 participants (mean age = 71.9 years, SD = 7.2) from the Alzheimer’s Disease Neuroimaging Initiative were classified by the Amyloid-β/Tau/Neurodegeneration framework into no Alzheimer’s disease pathology (n = 176), suspected non-Alzheimer’s disease pathophysiology (n = 87), or Alzheimer’s disease continuum (n = 300) groups. Participants completed baseline neuropsychological assessment, plasma/CSF biomarker collection, and Magnetic Resonance Imaging. Analyses explored the relative contributions of biomarkers to episodic memory and executive function performance and whether relationships varied by Amyloid-β/Tau/Neurodegeneration group status. Across all participants, neurofilament light chain (β ̂ = -0.14) and growth-associated protein 43 (β ̂ = -0.13) were the strongest biomarkers associated with episodic memory performance, such that greater levels were associated with worse episodic memory. There was a group by growth-associated protein 43 interaction with episodic memory: greater growth-associated protein 43 was associated with lower episodic memory performance in participants classified as Alzheimer’s disease continuum relative to the no Alzheimer’s disease pathology group (β ̂ = -0.26). No robust associations between biomarkers and executive function performance or between sTREM2, white matter hyperintensity volume, and cognition were observed. Biomarkers of neuro-axonal injury and synaptic dysfunction may independently contribute to episodic memory performance across participants with differing Amyloid-β/Tau/Neurodegeneration profiles. Growth-associated protein 43 may predict worse episodic memory performance in participants with greater Alzheimer’s disease pathology. These biomarkers of neuronal dysfunction may serve as domain-specific cognitive correlates in the context of Alzheimer’s disease biomarker status.
- 18 September 2024
- Published by Center for Open Science in PsyArXiv
Open AccessNeuronal and Glial Dysfunction, White Matter Hyperintensities, and Cognition in Aging and Alzheimer’s Disease
This cross-sectional study examined associations between multiple fluid biomarkers of neuronal and glial dysfunction (plasma neurofilament light chain, CSF growth-associated protein 43, CSF soluble triggering receptor expressed on myeloid cells 2 [sTREM2]), total white matter hyperintensity volume, and episodic memory and executive function performance in the context of Alzheimer’s disease biomarker status. 563 participants (mean age = 71.9 years, SD = 7.2) from the Alzheimer’s Disease Neuroimaging Initiative were classified by the Amyloid-β/Tau/Neurodegeneration framework into no Alzheimer’s disease pathology (n = 176), suspected non-Alzheimer’s disease pathophysiology (n = 87), or Alzheimer’s disease continuum (n = 300) groups. Participants completed baseline neuropsychological assessment, plasma/CSF biomarker collection, and Magnetic Resonance Imaging. Analyses explored the relative contributions of biomarkers to episodic memory and executive function performance and whether relationships varied by Amyloid-β/Tau/Neurodegeneration group status. Across all participants, neurofilament light chain (β ̂ = -0.14) and growth-associated protein 43 (β ̂ = -0.13) were the strongest biomarkers associated with episodic memory performance, such that greater levels were associated with worse episodic memory. There was a group by growth-associated protein 43 interaction with episodic memory: greater growth-associated protein 43 was associated with lower episodic memory performance in participants classified as Alzheimer’s disease continuum relative to the no Alzheimer’s disease pathology group (β ̂ = -0.26). No robust associations between biomarkers and executive function performance or between sTREM2, white matter hyperintensity volume, and cognition were observed. Biomarkers of neuro-axonal injury and synaptic dysfunction may independently contribute to episodic memory performance across participants with differing Amyloid-β/Tau/Neurodegeneration profiles. Growth-associated protein 43 may predict worse episodic memory performance in participants with greater Alzheimer’s disease pathology. These biomarkers of neuronal dysfunction may serve as domain-specific cognitive correlates in the context of Alzheimer’s disease biomarker status.
- Open Access
- 25 August 2023
- Published by Center for Open Science in PsyArXiv
Baseline Frontoparietal Gray Matter Volume Predicts Executive Function Performance in Aging and Mild Cognitive Impairment at 24-month Follow-Up
Background: Executive dysfunction in mild cognitive impairment (MCI) has been associated with gray matter atrophy. Prior studies have yielded limited insight into associations between gray matter volume and executive function in early and late amnestic MCI (aMCI).Objective: To examine the relative importance of predictors of executive function at 24-months and relationships between baseline regional gray matter volume and executive function performance at 24-month follow-up in non-demented older adults.Methods: 147 participants from the Alzheimer’s Disease Neuroimaging Initiative (mean age=70.6 years) completed brain Magnetic Resonance Imaging and neuropsychological testing and were classified as cognitively normal (n=49), early aMCI (n=60), or late aMCI (n=38). Analyses explored the importance of demographic, APOE-ε4, biomarker (p-tau/Aβ42, t-tau/Aβ42), and gray matter regions-of-interest (ROI) variables to 24-month executive function, whether ROIs predicted executive function, and whether relationships varied by baseline diagnostic status.Results: Across all participants, baseline anterior cingulate cortex and superior parietal lobule volumes were the strongest predictors of 24-month executive function performance. In early aMCI, anterior cingulate cortex volume was the strongest predictor and demonstrated a significant interaction such that lower volume related to worse 24-month executive function in early aMCI. Educational attainment and inferior frontal gyrus volume were the strongest predictors of 24-month executive function performance for cognitively normal and late aMCI groups, respectively.Conclusion: Baseline frontoparietal gray matter regions were significant predictors of executive function performance in the context of aMCI and may identify those at risk of Alzheimer’s disease. Anterior cingulate cortex volume may predict executive function performance in early aMCI.
- 25 August 2023
- Published by Center for Open Science in PsyArXiv
Open AccessBaseline Frontoparietal Gray Matter Volume Predicts Executive Function Performance in Aging and Mild Cognitive Impairment at 24-month Follow-Up
Background: Executive dysfunction in mild cognitive impairment (MCI) has been associated with gray matter atrophy. Prior studies have yielded limited insight into associations between gray matter volume and executive function in early and late amnestic MCI (aMCI).Objective: To examine the relative importance of predictors of executive function at 24-months and relationships between baseline regional gray matter volume and executive function performance at 24-month follow-up in non-demented older adults.Methods: 147 participants from the Alzheimer’s Disease Neuroimaging Initiative (mean age=70.6 years) completed brain Magnetic Resonance Imaging and neuropsychological testing and were classified as cognitively normal (n=49), early aMCI (n=60), or late aMCI (n=38). Analyses explored the importance of demographic, APOE-ε4, biomarker (p-tau/Aβ42, t-tau/Aβ42), and gray matter regions-of-interest (ROI) variables to 24-month executive function, whether ROIs predicted executive function, and whether relationships varied by baseline diagnostic status.Results: Across all participants, baseline anterior cingulate cortex and superior parietal lobule volumes were the strongest predictors of 24-month executive function performance. In early aMCI, anterior cingulate cortex volume was the strongest predictor and demonstrated a significant interaction such that lower volume related to worse 24-month executive function in early aMCI. Educational attainment and inferior frontal gyrus volume were the strongest predictors of 24-month executive function performance for cognitively normal and late aMCI groups, respectively.Conclusion: Baseline frontoparietal gray matter regions were significant predictors of executive function performance in the context of aMCI and may identify those at risk of Alzheimer’s disease. Anterior cingulate cortex volume may predict executive function performance in early aMCI.